Free Trial

4D Molecular Therapeutics (FDMT) Competitors

4D Molecular Therapeutics logo
$3.95 -0.29 (-6.84%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$4.03 +0.08 (+1.90%)
As of 07/7/2025 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FDMT vs. SION, GYRE, PHAT, ANAB, IMTX, TRVI, NUVB, DAWN, GHRS, and STOK

Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Sionna Therapeutics (SION), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), AnaptysBio (ANAB), Immatics (IMTX), Trevi Therapeutics (TRVI), Nuvation Bio (NUVB), Day One Biopharmaceuticals (DAWN), GH Research (GHRS), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry.

4D Molecular Therapeutics vs. Its Competitors

4D Molecular Therapeutics (NASDAQ:FDMT) and Sionna Therapeutics (NASDAQ:SION) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

4D Molecular Therapeutics presently has a consensus price target of $29.56, suggesting a potential upside of 648.24%. Sionna Therapeutics has a consensus price target of $38.50, suggesting a potential upside of 83.68%. Given 4D Molecular Therapeutics' higher probable upside, research analysts plainly believe 4D Molecular Therapeutics is more favorable than Sionna Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4D Molecular Therapeutics
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60
Sionna Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Sionna Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. Sionna Therapeutics' return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
4D Molecular Therapeutics-767,126.06% -33.26% -30.68%
Sionna Therapeutics N/A N/A N/A

Sionna Therapeutics has lower revenue, but higher earnings than 4D Molecular Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D Molecular Therapeutics$40K4,575.09-$160.87M-$3.18-1.24
Sionna TherapeuticsN/AN/A-$61.69MN/AN/A

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 3.9% of Sionna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, 4D Molecular Therapeutics had 3 more articles in the media than Sionna Therapeutics. MarketBeat recorded 8 mentions for 4D Molecular Therapeutics and 5 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 1.15 beat 4D Molecular Therapeutics' score of 0.06 indicating that Sionna Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
4D Molecular Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Sionna Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

4D Molecular Therapeutics and Sionna Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get 4D Molecular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FDMT vs. The Competition

Metric4D Molecular TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$196.42M$2.43B$5.52B$9.02B
Dividend YieldN/A1.78%5.24%4.08%
P/E Ratio-1.248.7527.1920.04
Price / Sales4,575.09473.55395.22100.83
Price / CashN/A21.7726.2128.59
Price / Book0.364.497.925.55
Net Income-$160.87M$31.26M$3.17B$248.49M
7 Day Performance-4.82%1.27%1.79%4.87%
1 Month Performance-9.20%2.46%1.28%6.63%
1 Year Performance-81.62%-0.29%33.32%20.38%

4D Molecular Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FDMT
4D Molecular Therapeutics
2.2486 of 5 stars
$3.95
-6.8%
$29.56
+648.2%
-81.3%$196.42M$40K-1.24120
SION
Sionna Therapeutics
N/A$17.35
+9.5%
$38.50
+121.9%
N/A$698.93MN/A0.0035Positive News
GYRE
Gyre Therapeutics
0.082 of 5 stars
$7.35
-0.9%
N/A-38.7%$695.68M$105.76M367.6840
PHAT
Phathom Pharmaceuticals
3.4413 of 5 stars
$9.59
-1.5%
$17.50
+82.5%
-15.9%$679.99M$55.25M-1.83110
ANAB
AnaptysBio
2.2738 of 5 stars
$22.20
-1.2%
$42.38
+90.9%
-5.3%$660.18M$91.28M-4.58100
IMTX
Immatics
2.3921 of 5 stars
$5.38
-0.9%
$14.67
+172.6%
-52.9%$660.02M$168.65M-31.65260Positive News
TRVI
Trevi Therapeutics
3.1092 of 5 stars
$5.47
-2.7%
$20.29
+270.9%
+130.6%$659.19MN/A-12.1620
NUVB
Nuvation Bio
3.5826 of 5 stars
$1.96
+1.3%
$7.17
+266.6%
-31.4%$656.71M$7.87M-0.8360Gap Up
High Trading Volume
DAWN
Day One Biopharmaceuticals
1.6934 of 5 stars
$6.50
+0.5%
$30.57
+370.3%
-51.6%$655.82M$131.16M-9.1560
GHRS
GH Research
1.5624 of 5 stars
$12.19
-2.0%
$32.00
+162.5%
+27.7%$647.23MN/A-15.4310Analyst Upgrade
STOK
Stoke Therapeutics
3.9941 of 5 stars
$11.35
-2.4%
$23.20
+104.4%
-10.9%$634.96M$190.91M14.37100

Related Companies and Tools


This page (NASDAQ:FDMT) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners